| abstract |
The present invention relates to interferon-free therapies for the treatment of HCV. Preferably, the duration of the treatment is reduced, for example to a duration not exceeding 12 weeks. In one aspect, the treatment comprises administering to a HCV-infected subject at least two direct-acting antiviral agents, the treatment for 12 weeks and not including the administration of interferon or ribavirin. and said at least two direct acting antiviral agents comprising (a) compound 1 or a pharmaceutically acceptable salt thereof and (b) compound 2 or a pharmaceutically acceptable salt thereof. |